Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: purified talc; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; erythrosine; titanium dioxide; lactose monohydrate; brilliant blue fcf; purified water; sodium lauryl sulfate; gelatin - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 30 mg - capsule, enteric - excipient ingredients: purified talc; macrogol 6000; hyprolose; titanium dioxide; polysorbate 80; methacrylic acid copolymer; sucrose; maize starch; magnesium carbonate hydrate; colloidal anhydrous silica; brilliant blue fcf; purified water; sorbitan monolaurate; erythrosine; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adults . 1. healing and long-term management of reflux oesophagitis. . 2. healing and long-term management for patients with duodenal ulcer. . 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. . 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). . 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric patients 1 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . 2. healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 15 mg - capsule, enteric - excipient ingredients: hyprolose; polysorbate 80; magnesium carbonate hydrate; sucrose; colloidal anhydrous silica; purified talc; maize starch; macrogol 6000; titanium dioxide; methacrylic acid copolymer; purified water; sorbitan monolaurate; allura red ac; gelatin; sodium lauryl sulfate; fast green fcf; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adults . 1. healing and long-term management of reflux oesophagitis. . 2. healing and long-term management for patients with duodenal ulcer. . 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. . 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). . 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric patients 1 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . 2. healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole magnesium, quantity: 22.252 mg - capsule, enteric - excipient ingredients: triethyl citrate; polysorbate 80; sodium hydroxide; glyceryl monostearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); sucrose; hyprolose; crospovidone; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - for relief of frequent heartburn and other symptoms of gastro-oesophageal reflux disease.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

innova captab limited, india - cefixime trihydrate equivalent to cefixime - hard gelatin capsules - 400 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - indometacin, quantity: 25 mg - capsule, hard - excipient ingredients: sodium starch glycollate; sodium lauryl sulfate; magnesium stearate; lactose monohydrate; titanium dioxide; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - arthrexin is indicated in active stages of rheumatoid arthritis, osteoarthritis, degenerative joint disease of the hip, ankylosing spondylitis and gout. it is also indicated for: acute musculoskeletal disorders, such as bursitis, tendonitis, synovitis, tenosynovitis, capsulitis of the shoulder, sprains and strains; low back pain (commonly referred to as lumbago); inflammation, pain and oedema following orthopaedic surgical procedures and nonsurgical procedures associated with reduction and immobilisation of fractures or dislocations; pain and associated symptoms of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - indometacin, quantity: 25 mg - capsule, hard - excipient ingredients: sodium starch glycollate; sodium lauryl sulfate; magnesium stearate; lactose monohydrate; titanium dioxide; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - arthrexin is indicated in active stages of rheumatoid arthritis, osteoarthritis, degenerative joint disease of the hip, ankylosing spondylitis and gout. it is also indicated for: acute musculoskeletal disorders, such as bursitis, tendonitis, synovitis, tenosynovitis, capsulitis of the shoulder, sprains and strains; low back pain (commonly referred to as lumbago); inflammation, pain and oedema following orthopaedic surgical procedures and nonsurgical procedures associated with reduction and immobilisation of fractures or dislocations; pain and associated symptoms of primary dysmenorrhoea.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

atra pharmaceuticals limited, india - deferiprone - hard gelatin capsules - 500

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: gelatin; triethyl citrate; titanium dioxide; sucrose; brilliant blue fcf; hypromellose phthalate; purified talc; hypromellose; iron oxide yellow; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd). treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; brilliant blue fcf; purified talc; hypromellose; gelatin; titanium dioxide; sucrose; maize starch; propylene glycol; ethanol; indigo carmine; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd). treatment of generalised anxiety disorder (gad).